Swedish Orphan Biovitrum AB (publ)
SOBI · Nasdaq Stockholm
Public Market Listing
Live quotes, historical charts, and market capitalization for Swedish Orphan Biovitrum AB (publ) are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(6 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | Interleukin-1 Receptor AntagonistProtein / enzyme therapeutic | Rheumatoid Arthritis | |
Olezarsen(Tryngolza) | Approved | APOC3RNA / oligonucleotide | Familial Chylomicronemia SyndromeSevere HypertriglyceridemiaCardiovascular Disease / Dyslipidemia Hypertriglyceridemia |
Pegcetacoplan(Empaveli) | Approved | Complement C3Peptide | Complement-Mediated Renal DiseaseParoxysmal Nocturnal Hemoglobinuria |
Inotersen(Tegsedi) | US approval withdrawn | Transthyretin (TTR)RNA / oligonucleotide | Transthyretin-Mediated Amyloidosis Transthyretin Amyloidosis with Polyneuropathy |
| Phase 3 | APOC3 mRNARNA / oligonucleotide | Familial Chylomicronemia SyndromeSevere Hypertriglyceridemia | |
| Phase 2 | KIR3DL2Monoclonal antibody | Cutaneous T-Cell Lymphoma |
Upcoming events
(7 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (3)
March 2027 (1)
What to watch
June 2027 (1)
What to watch
July 2027 (1)
What to watch
2028 (2)
2030 (1)
August 2030 (1)
What to watch
2031 (1)
January 2031 (1)
What to watch
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
No financial reports recorded.